Healthcare Resource Utilization and Costs of Relapsed or Refractory Patients with Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma Treated with Ibrutinib

MLA

Xiaoqin Yang, et al. “Healthcare Resource Utilization and Costs of Relapsed or Refractory Patients with Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma Treated with Ibrutinib.” Blood, vol. 140, Nov. 2022, pp. 10911–12. EBSCOhost, https://doi.org/10.1182/blood-2022-167262.

APA

Xiaoqin Yang, Enrico Zanardo, Dominique Lejeune, Enrico De Nigris, Eric Sarpong, Mohammed Z.H. Farooqui, & François Laliberté. (2022). Healthcare Resource Utilization and Costs of Relapsed or Refractory Patients with Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma Treated with Ibrutinib. Blood, 140, 10911–10912. https://doi.org/10.1182/blood-2022-167262

Chicago

Xiaoqin Yang, Enrico Zanardo, Dominique Lejeune, Enrico De Nigris, Eric Sarpong, Mohammed Z.H. Farooqui, and François Laliberté. 2022. “Healthcare Resource Utilization and Costs of Relapsed or Refractory Patients with Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma Treated with Ibrutinib.” Blood 140 (November): 10911–12. doi:10.1182/blood-2022-167262.